Recent Advances in the Treatment of Prostate Cancer : Episode 17
Results of the VISION Trial and Real-World Use of 177Lu-PSMA-617 in mCRPC
Reflections on results of the VISION trial, which utilized 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer.
EP: 1.Overview of Improvements in Prostate Cancer Management
EP: 2.Optimizing Use of PSMA PET Imaging and PSADT in Prostate Cancer
EP: 3.Evolving Treatment Landscape of Nonmetastatic CRPC
EP: 4.Factors in Selecting Novel AR-Targeted Therapy for Nonmetastatic CRPC
EP: 5.Nonmetastatic Castration-Resistant Prostate Cancer: Quality of Life Measures
EP: 6.Monitoring Strategies in Nonmetastatic CRPC
EP: 7.Overview of Treatment for Metastatic HSPC
EP: 8.Role of Micronized Abiraterone in Metastatic HSPC
EP: 9.Selecting Optimal Therapy for mHSPC: Design of the ARASENS Trial
EP: 10.Interpreting Data From the ARASENS Trial in Metastatic HSPC
EP: 11.Overview of Therapy for mCRPC: PARP Inhibitors
EP: 12.DNA Alterations and Selection of PARP Inhibitors in mCRPC
EP: 13.Metastatic CRPC: Utility of Imaging as a Biomarker
EP: 14.Selecting Among Novel Imaging Options in Metastatic CRPC
EP: 15.Role of 177Lu-PSMA-617 in mCRPC and Bone Metastases
EP: 16.Addressing Bone and Visceral Metastases in Metastatic CRPC
Now Viewing
EP: 17.Results of the VISION Trial and Real-World Use of 177Lu-PSMA-617 in mCRPC
EP: 18.Prostate Cancer Management: Future Directions in Care
Related Videos
Related Content
